Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. develops monoclonal antibody therapies for serious viral infectious diseases, with an initial focus on SARS-CoV-2. Company news commonly covers PEMGARDA (pemivibart), which received U.S. FDA emergency use authorization for pre-exposure prevention of COVID-19 in certain immunocompromised individuals, and pipeline work involving VYD2311 for COVID-19, VBY329 for RSV, and VMS063 for measles.
Updates also address clinical-study design and tolerability research, antibody platform presentations, financial results and corporate updates, public education efforts around antibodies and immune health, and Nasdaq inducement equity grants under the company’s 2026 Inducement Plan.
Invivyd, formerly Adagio Therapeutics, announced a name change reflecting its focus on developing anti-viral antibodies that enhance immunity against viral diseases, starting with COVID-19. The company will trade under the new ticker symbol IVVD on Nasdaq starting September 13, 2022. Invivyd aims to deliver effective antibody solutions through its advanced discovery platform, which integrates evolutionary virology and antibody engineering. Additionally, the company is working on multiple candidates for seasonal influenza prevention.